surmount-1 tirzepatide 15 mg weight loss percent SURMOUNT-1: Provides Significant, Sustained in Obesity Relationship of early rapid weight

Reduces Arterial Stiffness Arterial stiffness is a key factor in hypertension

In the same study, Beyond the scale with Wegovy HD 1 Patients taking Wegovy HD pen 7.2 mg experienced improvements across most cardiometabolic risk factors Confirmatory secondary end points: Change from baseline to week 72 in 1 : Waist circumference: 5.6-inch reduction 2.2-inch reduction with placebo Supportive secondary end points: Change from baseline to week 72 in 1 : Lipid profile: Total cholesterol 3.4% reduction 4.0% reduction with placebo LDL 3.5% reduction 4.8% reduction with placebo HDL 9.5% increase 0.5% decrease with placebo Triglycerides 16.4% reduction 0.9% reduction with placebo Systolic blood pressure: 10.1 mm Hg reduction 4.8 mm Hg reduction with placebo Diastolic blood pressure: 4.5 mm Hg reduction 1.8 mm Hg reduction with placebo A1c: 0.3% reduction 0% change with placebo Safety end point: Change in 1 : Heart rate: 0.5 bpm increase 0.6 bpm reduction with placebo Wegovy is not indicated to treat hypertension, type 2 diabetes, or dyslipidemia

doi: 10.3389/fendo.2024.1330936 Received 31 October 2023 Accepted 02 January 2024 Published 06 February 2024 Volume 15 - 2024 Edited by Julianne Hall, Quinnipiac University, United States Reviewed by Eric Morris Bomberg, University of Minnesota, United States Michihiro Takahashi, Takahashi Psychiatric Clinic, Japan Updates Copyright 2024 Chen, Cai, Zou and Fu

CMV specific cytokine release assay in whole blood is optimized by combining synthetic CMV peptides and toll like receptor agonists